Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Kaifeng Liu, Meijia Li, Yudong Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 45

Showing 26-50 of 45 citing articles:

Future AI Will Be Able to Predict Antibody-Drug Conjugate Response in Oncology
Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, et al.
(2024)
Open Access | Times Cited: 1
Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis
Guillermo Villacampa, Pablo Cresta Morgado, L. Carità, et al.
Cancer Treatment Reviews (2024) Vol. 131, pp. 102847-102847
Closed Access | Times Cited: 1
Beyond ADCs: Harnessing Bispecific Antibodies to Directly Induce Apoptosis for Targeted Tumor Eradication
Victor S. Goldmacher, Iosif M. Gershteyn, Yelena Kovtun
Antibody Therapeutics (2024) Vol. 7, Iss. 4, pp. 351-360
Open Access | Times Cited: 1
Generation of binder-format-payload conjugate-matrices by antibody chain-exchange
Vedran Vasic, Steffen Dickopf, Nadine Spranger, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
A Complete Sojourn of Monoclonal Antibodies: AI, Rare Diseases / Disorders and Immunotoxic Effects
Sonakshi Garg, G. K. Garg, Preeti Patel, et al.
Current Proteomics (2024) Vol. 21, Iss. 2, pp. 58-78
Closed Access
Varianten biotechnologischer Arzneistoffe in der Dermatologie
Johannes Wohlrab, Adina Eichner
Deleted Journal (2024) Vol. 75, Iss. 10, pp. 775-780
Closed Access
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Caroline Taylor, Kamai M. Patterson, Devira Friedman, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3071-3071
Open Access
Chemo-selective modification of cysteine residue: synthesis and application in the discovery of potential drug candidates
Yanyan Liao, Xuefeng Jiang
(2024), pp. 540-554
Closed Access
Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art
Floriana Camarda, Mariachiara Paderno, Maria Chiara Cannizzaro, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Understanding the chemistry & pharmacology of antibody–drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives
Sharada Sawant, Gaurav Gopal Naik, Alakh N. Sahu, et al.
Medical Oncology (2024) Vol. 41, Iss. 12
Closed Access
Protective effect of osteogenic growth peptide functionalized tetrahedral DNA nanostructure on bone marrow and bone formation ability in chemotherapy-induced myelosuppressive mice
Tianxu Zhang, Dexuan Xiao, Mi Zhou, et al.
Chinese Chemical Letters (2024), pp. 110594-110594
Closed Access
The Emerging Era of Molecular Medicine
Heming Tang, Ying Zhang, Yanyuan Wu, et al.
ACS Nano (2024) Vol. 18, Iss. 45, pp. 30911-30918
Closed Access
Production of site-specific antibody conjugates using metabolic glycoengineering and novel Fc glycovariants
Zachary J. Bernstein, Taylor Gierke, Kris Dammen‐Brower, et al.
Journal of Biological Chemistry (2024), pp. 108005-108005
Open Access
Branched Linkers for Homogeneous Antibody-Drug Conjugates: How Long Is Long Enough?
Evgeny L. Gulyak, О. В. Комарова, Yuri Prokopenko, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13356-13356
Open Access
Therapeutic potential of antibody-drug conjugates possessing bifunctional anti-inflammatory action in the pathogenies of rheumatoid arthritis
Tanu Dixit, Anuradha Vaidya, Selvan Ravindran
Arthritis Research & Therapy (2024) Vol. 26, Iss. 1
Open Access
Insights and therapeutic advances in pancreatic cancer: the role of electron microscopy in decoding the tumor microenvironment
Hong Dai, Xingxuan Chen, Jiawen Yang, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access
Monoclonal Antibody Therapies in Cancer Immunotherapy
Charuwan Thanawiroon, Bancha Yingngam
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 419-472
Closed Access
Simple theranostics nanoagent for precision suppression of tumor growth and Metastasis: A traditional fermented product having a novel functional breakthrough
Pengmin Liu, Rong Dai, Juan Li, et al.
Chemical Engineering Journal (2024) Vol. 500, pp. 156545-156545
Closed Access
Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy
Xue Jiang, Wan Najbah Nik Nabil, Yufei Ze, et al.
Phytotherapy Research (2024)
Closed Access
Small molecule-drug conjugates: Mechanistic insights and strategic design for enhanced cancer therapy
Jiawei Zhu, Yucheng Xiong, Xiaoxue Bai, et al.
Chinese Chemical Letters (2024), pp. 110799-110799
Closed Access
Previous Page - Page 2

Scroll to top